Figure 10. Drug synergy of EZH2 inhibitor GSK126 and small-molecule compounds.

(A) Delta Bliss Sum Negative (DBSumNeg) score of drug synergy analysis with GSK126 treatment in Kelly cells on day 6 in vitro. The synergistic combinations were estimated based on DBSumNeg score cutoff < –3. Results are representative of 3 independent experiments. (B) Combination index analysis of GSK126 and panobinostat in 4 neuroblastoma cell lines. Dotted red line is the line of additivity between antagonism (>0) and synergy (<0). Light blue is significant synergy (log₁₀ [CI] < –0.10), and dark blue is strong synergy (log₁₀ [CI] < –0.22). Results are representative of 2–3 independent experiments. (C) Relative mRNA expression changes upon combination treatment of GSK126 and panobinostat, compared with single-agent treatment. All expression is normalized to DMSO. Results are representative of 3 independent experiments; mean ± SD of 4 technical replicates is shown.